Sami Inkinen

It is a tool in a toolkit for type two diabetes and in some cases for obesity. So I just want to be very clear. And obviously Virta, Our providers practice evidence-based medicine. So anything I say next isn't going to be like, oh, you know, drugs are bad in all cases. No, that is not the case. But to answer your question specifically, and this is all data that's published in peer reviews.

So if anyone wants to sort of double check, you can go to VirtaHealth.com and slash research and find out published in peer review results. But indeed. So what we've been able to show is that as we run our nutrition program, among our patients, the following things either improve or get reversed. Obviously, type 2 diabetes. So that's glycemic control. So blood sugar comes down. Hypertension.

So if anyone wants to sort of double check, you can go to VirtaHealth.com and slash research and find out published in peer review results. But indeed. So what we've been able to show is that as we run our nutrition program, among our patients, the following things either improve or get reversed. Obviously, type 2 diabetes. So that's glycemic control. So blood sugar comes down. Hypertension.

So if anyone wants to sort of double check, you can go to VirtaHealth.com and slash research and find out published in peer review results. But indeed. So what we've been able to show is that as we run our nutrition program, among our patients, the following things either improve or get reversed. Obviously, type 2 diabetes. So that's glycemic control. So blood sugar comes down. Hypertension.

So blood pressure comes down. Inflammation comes down. So this is CRP, C-reactive protein, a white blood cell count. And we also have an unpublished paper looking at 16 inflammation proteins of which almost all improve, which is unheard of, better than Humira. That's unpublished, so that's a caveat. Depressive symptoms improve. Sleep apnea improves, so it gets reversed. Knee pain goes down.

So blood pressure comes down. Inflammation comes down. So this is CRP, C-reactive protein, a white blood cell count. And we also have an unpublished paper looking at 16 inflammation proteins of which almost all improve, which is unheard of, better than Humira. That's unpublished, so that's a caveat. Depressive symptoms improve. Sleep apnea improves, so it gets reversed. Knee pain goes down.

So blood pressure comes down. Inflammation comes down. So this is CRP, C-reactive protein, a white blood cell count. And we also have an unpublished paper looking at 16 inflammation proteins of which almost all improve, which is unheard of, better than Humira. That's unpublished, so that's a caveat. Depressive symptoms improve. Sleep apnea improves, so it gets reversed. Knee pain goes down.

Cardiovascular disease risk markers and 12-year cardiovascular risk. goes down, kidney and liver function improves. So we looked at EGFR and we can't really say that we can, it would be a little bit overreaching to say we reverse kidney disease, but we have shown that we improve kidney function and same with liver function. So when you look at these broad spectrum metabolic health improvements.

Cardiovascular disease risk markers and 12-year cardiovascular risk. goes down, kidney and liver function improves. So we looked at EGFR and we can't really say that we can, it would be a little bit overreaching to say we reverse kidney disease, but we have shown that we improve kidney function and same with liver function. So when you look at these broad spectrum metabolic health improvements.

Cardiovascular disease risk markers and 12-year cardiovascular risk. goes down, kidney and liver function improves. So we looked at EGFR and we can't really say that we can, it would be a little bit overreaching to say we reverse kidney disease, but we have shown that we improve kidney function and same with liver function. So when you look at these broad spectrum metabolic health improvements.

It's basically the same list that the GLP-1 manufacturers are now showing, that we either improve or reverse. And we've already published this data. So what can we conclude? Again, I'm not the medical doctor here, so maybe Krisma can kind of cover me up here a little bit. But basically what we can show is

It's basically the same list that the GLP-1 manufacturers are now showing, that we either improve or reverse. And we've already published this data. So what can we conclude? Again, I'm not the medical doctor here, so maybe Krisma can kind of cover me up here a little bit. But basically what we can show is

It's basically the same list that the GLP-1 manufacturers are now showing, that we either improve or reverse. And we've already published this data. So what can we conclude? Again, I'm not the medical doctor here, so maybe Krisma can kind of cover me up here a little bit. But basically what we can show is

It is possible to achieve the same broad metabolic health improvements as DLP once may or may not, nutritionally, 100% nutritionally. Therefore, It is not the exogenous molecule that is achieving these results alone because it's possible to achieve the same results nutritionally. Now we can still debate the mechanism. Is it all about the weight loss or are there other things in play?

It is possible to achieve the same broad metabolic health improvements as DLP once may or may not, nutritionally, 100% nutritionally. Therefore, It is not the exogenous molecule that is achieving these results alone because it's possible to achieve the same results nutritionally. Now we can still debate the mechanism. Is it all about the weight loss or are there other things in play?

It is possible to achieve the same broad metabolic health improvements as DLP once may or may not, nutritionally, 100% nutritionally. Therefore, It is not the exogenous molecule that is achieving these results alone because it's possible to achieve the same results nutritionally. Now we can still debate the mechanism. Is it all about the weight loss or are there other things in play?

And our hypothesis is there are other things in play, but again, such as information, reduce information. But we can achieve the same things nutritionally. Which I think, again, is a very important message to be heard because in the next year and two, there's going to be headlines. Oh, GLP-1s now improve the eighth new thing. And the answer is, guess what? Nutrition improves all those things.

And our hypothesis is there are other things in play, but again, such as information, reduce information. But we can achieve the same things nutritionally. Which I think, again, is a very important message to be heard because in the next year and two, there's going to be headlines. Oh, GLP-1s now improve the eighth new thing. And the answer is, guess what? Nutrition improves all those things.

And our hypothesis is there are other things in play, but again, such as information, reduce information. But we can achieve the same things nutritionally. Which I think, again, is a very important message to be heard because in the next year and two, there's going to be headlines. Oh, GLP-1s now improve the eighth new thing. And the answer is, guess what? Nutrition improves all those things.

And then finally, I will say, again, there's a place for these trucks. GLP-1 is a tool in a toolkit. But I think this statement holds true, which is, We don't know the short, the midterm and the long-term side effects of exogenous drugs, but we know the side effects of healthy food. Guess what? Happier, better, longer life.